checklistOver time, many of your patients who currently receive IVIG infusions with GAMMAGARD S/D [Immune Globulin Intravenous (Human)] Solvent Detergent Treated may be transitioned to GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)]10%. Baxter will continue to produce small amounts of GAMMAGARD S/D, only for use with patients who are highly sensitive to IgA.
GAMMAGARD LIQUID is the result of several years of clinical research and is the latest step in Baxter’s ongoing effort toward advancing the science of IVIG. Following the steps on this checklist can help you educate your patients about GAMMAGARD LIQUID.
- Ask the infusion centers and home healthcare organizations that currently provide GAMMAGARD S/D to your patients when they may be offering GAMMAGARD LIQUID
- Use the IgA sensitive participant profile form to let providers know that you approve of switching your patient to GAMMAGARD LIQUID
- Talk to your patients about:
•The GAMMAGARD LIQUID formulation, with no added sugars, no added salt, no
added preservatives, and latex-free packaging.1
•The GAMMAGARD LIQUID dedicated three-step process specifically designed for viral
inactivation/removal1 - Visit www.immunedisease.com for more information
- If you have questions, call Baxter Medical Affairs at 1-866-424-6724
Transition Resources
To educate yourself, your patients, and your office staff about the transition from GAMMAGARD S/D to GAMMAGARD LIQUID, download and read the letters below.
- Read this Letter to Healthcare Providers for more information on helping patients make the transition to GAMMAGARD LIQUID. It includes an HCP Transition Checklist and the Transition Approval Form.
- Print out and offer this Letter to Patients to provide them with more information on making the transition to GAMMAGARD LIQUID. It includes an Patient Transition Checklist
- Share this Letter to Healthcare Administrators to inform hospital, clinic, and office staff about the transition to GAMMAGARD LIQUID.
GAMMAGARD LIQUID 10% has an average IgA content of 37 µg/mL. Baxter continues to offer GAMMAGARD S/D, with a maximum IgA content of 2.2 µg/mL for 5% formulation.
 |
To view PDF, you will need Adobe® Acrobat® Reader® software. |